| Entry |
|
|---|
| Name |
Almotriptan malate (USP);
Axert (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C17H25N3O2S. C4H6O5
|
|---|
| Exact mass |
469.1883
|
|---|
| Mol weight |
469.5517
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Product (DG00839): | D02825<US> |
|
|---|
| Efficacy |
Antimigraine, Serotonin receptor agonist |
|---|
| Comment |
Sumatriptan derivative
Acute treatment of migraine attacks
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N02 ANALGESICS
N02C ANTIMIGRAINE PREPARATIONS
N02CC Selective serotonin (5HT1) agonists
N02CC05 Almotriptan
D02825 Almotriptan malate (USP) <US>
USP drug classification [BR:br08302]
Antimigraine Agents
Serotonin (5-HT) Receptor Agonists
Almotriptan
D02825 Almotriptan malate (USP)
Drug groups [BR:br08330]
Analgesic
DG01484 5-HT1B-receptor agonist
DG00839 Almotriptan
D02825 Almotriptan malate
DG01485 5-HT1D-receptor agonist
DG00839 Almotriptan
D02825 Almotriptan malate
DG01518 5-HT1B/1D-receptor agonist
DG00839 Almotriptan
D02825 Almotriptan malate
DG01943 Triptan
DG00839 Almotriptan
D02825 Almotriptan malate
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00839 Almotriptan
D02825 Almotriptan malate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00839 Almotriptan
D02825 Almotriptan malate
DG02917 MAO substrate
DG03178 MAOA substrate
DG00839 Almotriptan
D02825 Almotriptan malate
Unclassified
DG03306 FMO substrate
DG02950 FMO3 substrate
DG00839 Almotriptan
D02825 Almotriptan malate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Serotonin
HTR1B
D02825 Almotriptan malate (USP) <US>
HTR1D
D02825 Almotriptan malate (USP) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02825
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02825
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02825
Drug groups [BR:br08330]
Analgesic
DG01484 5-HT1B-receptor agonist
DG00839 Almotriptan
DG01485 5-HT1D-receptor agonist
DG00839 Almotriptan
DG01518 5-HT1B/1D-receptor agonist
DG00839 Almotriptan
DG01943 Triptan
DG00839 Almotriptan
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00839 Almotriptan
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00839 Almotriptan
DG02917 MAO substrate
DG03178 MAOA substrate
DG00839 Almotriptan
Unclassified
DG03306 FMO substrate
DG02950 FMO3 substrate
DG00839 Almotriptan
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 32
1 O6a O 32.3870 -18.3686
2 C6a C 33.5912 -19.0639
3 C1c C 34.7956 -18.3686
4 C1b C 35.9998 -19.0639
5 C6a C 37.2041 -18.3686
6 O6a O 38.4085 -19.0639
7 O6a O 33.5912 -20.4544
8 O6a O 37.2041 -16.9782
9 O1a O 34.7956 -16.9783
10 C8y C 27.2363 -19.5213
11 C8y C 27.2363 -20.9261
12 C8y C 28.5707 -19.0999
13 C8x C 26.0422 -18.8188
14 N4x N 28.5707 -21.3475
15 C8x C 26.0422 -21.6284
16 C8x C 29.4136 -20.2236
17 C8y C 24.8481 -19.5213
18 C8x C 24.8481 -20.9261
19 C1b C 23.5839 -18.8188
20 S4a S 22.3898 -19.5213
21 O3c O 23.3732 -20.5046
22 O3c O 21.4065 -20.5046
23 N1y N 21.3979 -18.5267
24 C1x C 21.8322 -17.1908
25 C1x C 20.6958 -16.3648
26 C1x C 19.5592 -17.1903
27 C1x C 19.9930 -18.5263
28 C1b C 28.5707 -17.6998
29 C1b C 29.7716 -17.0065
30 N1c N 29.7716 -15.5905
31 C1a C 30.9879 -14.8882
32 C1a C 28.5662 -14.8946
BOND 33
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 2 7 2
7 5 8 2
8 3 9 1
9 10 11 1
10 10 12 1
11 10 13 2
12 11 14 1
13 11 15 2
14 12 16 2
15 13 17 1
16 15 18 1
17 17 19 1
18 19 20 1
19 20 21 2
20 20 22 2
21 14 16 1
22 17 18 2
23 20 23 1
24 23 24 1
25 24 25 1
26 25 26 1
27 26 27 1
28 23 27 1
29 12 28 1
30 28 29 1
31 29 30 1
32 30 31 1
33 30 32 1
|
|---|
